Income Taxes and Tax Receivable Agreement |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Income Tax Disclosure [Abstract] | |
| Income Taxes and Tax Receivable Agreement | Income Taxes and Tax Receivable Agreement The provision for income taxes differs from the amount of income tax computed by applying the applicable U.S. statutory federal income tax rate of 21% and blended state tax rate to income (loss) before income taxes. This is due to Viant Technology LLC’s pass-through structure for U.S. income tax purposes in the current period and the valuation allowance applied against the deferred tax asset in prior-year periods through September 30, 2025. As of December 31, 2025, the Company released its valuation allowance and recorded no valuation allowance for the six months ended June 30, 2026. For the three and six months ended June 30, 2026, the Company recognized an income tax benefit of $0.8 million and $1.2 million, respectively, attributable to year-to-date loss and excess tax benefits on vested stock-based compensation that will be realized during the year, resulting in an effective tax rate of 29.3% and 22.5%, respectively. For the three and six months ended June 30, 2025, the Company recognized income tax benefits of $0.3 million and $0.4 million, respectively, attributable to year-to-date loss and excess tax benefit related to vested stock-based compensation, resulting in an effective tax rate of (19.4)% and 22.6%, respectively. In connection with its initial public offering ("IPO"), the Company entered into a Tax Receivable Agreement ("TRA") with Viant Technology LLC, continuing members of Viant Technology LLC and the TRA Representative (as defined in the TRA) on February 9, 2021. The total TRA liability as of June 30, 2026 was $12.9 million, all of which was classified as long-term. The total current and long-term portions of the TRA liability as of December 31, 2025 were $0.2 million and $12.2 million, respectively. On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law, which enacts significant changes to U.S. tax and related laws. Some of the provisions of the new tax law affecting corporations include, but are not limited to, expensing of domestic specified research or experimental expenditures and 100% bonus depreciation on eligible property acquired after January 19, 2025. The most impactful component of OBBBA to our Company is the ability to immediately expense domestic specified research or experimental expenditures, which is an annual election. The Company evaluates immediately expensing these costs in conjunction with our general operations and other book-to-tax differences on an annual basis. As of June 30, 2026, we are anticipating expensing these costs in its entirety. We will continue to apply OBBBA tax law changes as required or elected throughout the year.
|